Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma†
- Citation:
- Ann Oncol vol 27 (10) 1855-1860
- Year:
- 2016
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- http://annonc.oxfordjournals.org/content/early/2016/08/06/annonc.mdw281.abstract?keytype=ref&ijkey=OgzhlPdheHfK1AI
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 6
- Parents:
- 939
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- P30 CA008748, U10CA180791, U10CA180821, U10CA180882, 5U10CA180833, U10 CA180821, U10 CA180822, U10 CA180833, U10 CA180867
- Corr. Author:
- Authors:
- M. A. Dickson M. R. Mahoney W. D. Tap S. P. D'Angelo M. L. Keohan B. A. Van Tine M. Agulnik L. E. Horvath J. S. Nair G. K. Schwartz
- Networks:
- CA043, COLUMBIA, LAPS-MN026, LAPS-MO011, LAPS-NY016, SANFORD
- Study
- Alliance-A091102
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- soft tissue sarcoma, bone sarcoma, aurora kinase inhibitors, phase II clinical trials